Progenics Pharmaceuticals Inc PGNX.0 sold the rights for its constipation shot Relistor to Salix Pharmaceuticals Ltd (SLXP.O) within two months of former partner Pfizer Inc (PFE.N) returning it. Shares of the Tarrytown, New York-based company, which have risen 16 percent since Pfizer returned the rights on Dec. 10, were up 11 percent in morning trade on the Nasdaq. The deal, which does not include rights for the product in Japan, consists of $60 million in upfront payments and $90 million in milestone payments in exchange for rights on the injection that treats opioid induced constipation.
Source
